ATE440888T1 - Verfahren zur herstellung von glatiramer - Google Patents

Verfahren zur herstellung von glatiramer

Info

Publication number
ATE440888T1
ATE440888T1 AT05824006T AT05824006T ATE440888T1 AT E440888 T1 ATE440888 T1 AT E440888T1 AT 05824006 T AT05824006 T AT 05824006T AT 05824006 T AT05824006 T AT 05824006T AT E440888 T1 ATE440888 T1 AT E440888T1
Authority
AT
Austria
Prior art keywords
glatiramer
producing
producing glatiramer
Prior art date
Application number
AT05824006T
Other languages
English (en)
Inventor
Anup Ray
Hiren Patel
Johannes Ludescher
Mariappan Anbazhagan
Mahendra Patel
Ingolf Macher
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE440888T1 publication Critical patent/ATE440888T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05824006T 2004-10-29 2005-10-27 Verfahren zur herstellung von glatiramer ATE440888T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62334604P 2004-10-29 2004-10-29
US65137205P 2005-02-09 2005-02-09
US65153505P 2005-02-09 2005-02-09
US72390105P 2005-10-05 2005-10-05
PCT/US2005/039003 WO2006050122A1 (en) 2004-10-29 2005-10-27 Processes for preparing glatiramer

Publications (1)

Publication Number Publication Date
ATE440888T1 true ATE440888T1 (de) 2009-09-15

Family

ID=36046637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824006T ATE440888T1 (de) 2004-10-29 2005-10-27 Verfahren zur herstellung von glatiramer

Country Status (14)

Country Link
US (5) US20060154862A1 (de)
EP (1) EP1807467B1 (de)
JP (1) JP5297653B2 (de)
CN (1) CN101044188B (de)
AR (1) AR052321A1 (de)
AT (1) ATE440888T1 (de)
AU (1) AU2005302500B2 (de)
CA (1) CA2583589C (de)
DE (1) DE602005016292D1 (de)
ES (1) ES2331015T3 (de)
IL (2) IL182581A (de)
SI (1) SI1807467T1 (de)
TW (1) TWI307349B (de)
WO (1) WO2006050122A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1459065T1 (sl) 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2008006026A1 (en) * 2006-07-05 2008-01-10 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
WO2008157697A2 (en) 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
ES2537022T3 (es) 2008-08-07 2015-06-01 Sigma-Aldrich Co. Llc Preparación de polilisina y poliornitina de bajo peso molecular con alto rendimiento
JP2011530523A (ja) * 2008-08-07 2011-12-22 サイノファーム タイワン リミテッド 酢酸グラチラマーの合成
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
EP2414384B2 (de) 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Steuerung von copolymerzusammensetzungen
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
RS52367B (sr) * 2009-07-15 2012-12-31 Teva Pharmaceutical Industries Ltd. Formulacije glatiramer acetata smanjene zapremine i postupci primene
ES2612001T4 (es) 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
US20120282296A1 (en) * 2009-11-17 2012-11-08 Ares Trading Sa Methods for improving the design, bioavailability, and efficacy of directed sequence polymer compositions via serum protein-based detection of directed sequence polymer compositions
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CN102844325A (zh) * 2010-04-27 2012-12-26 雷迪博士实验室有限公司 多肽及其盐的制备
WO2012016042A2 (en) * 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Glatiramer acetate molecular weight markers
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
WO2012114167A1 (en) * 2011-02-24 2012-08-30 Biocon Limited Processes for the preparation of glatiramer acetate
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
AU2012330728A1 (en) * 2011-11-03 2014-06-26 Biocon Limited Process for the preparation of random polypeptides and employing circular dichroism as a guidance tool for the manufacture of glatiramer acetate
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
DK3433430T3 (da) 2016-03-23 2022-09-05 Alm Holding Co Batch-asfaltblandeanlæg
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN107082796B (zh) * 2017-05-02 2020-06-09 江苏大学 一种提纯蛋白酶解物中小分子多肽的方法
GB2579600B (en) 2018-12-05 2023-07-05 Byotrol Plc Anti-viral composition
BR112021026863A2 (pt) 2019-07-01 2022-03-03 Alm Holding Co Sistemas para processar material e para suprimir micro-ondas, métodos para processar material, para prover de modo portável material processado sob demanda e para fazer uma mistura betuminosa, produto, e, aparelho para tratar material
AU2022463711A1 (en) 2021-09-08 2024-03-07 A.L.M. Holding Company Microwave heating applied to mining and related features

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657972A (en) * 1952-09-06 1953-11-03 Robert B Woodward Copolymer of l-leucine and dl-phenylalanine
US3704282A (en) * 1971-04-09 1972-11-28 Sidney Spector Catecholamine antigens and antibodies specific therefor
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
HU174500B (hu) * 1976-05-05 1980-01-28 Richter Gedeon Vegyeszet Sposob poluchenija slozhnogo oktapeptidamid-sul'fatnogo ehfira kholecistokhinin-pankreozimina
JPS6053535A (ja) * 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3684333D1 (de) 1985-06-18 1992-04-16 Univ Emory Biologisch wirksame kopolymere.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
CA2009996A1 (en) 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en) 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
JP3169383B2 (ja) * 1996-01-16 2001-05-21 ルミゲン インク ホスファターゼ酵素で化学発光を生成させるための化合物、組成物および方法
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6514935B1 (en) * 1997-03-14 2003-02-04 President And Fellows Of Harvard Methods of treating hypertension
US6632541B2 (en) * 1998-02-10 2003-10-14 Sumitomo Chemical Company, Limited Olefin-based copolymer composition
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
IL141423A (en) * 1998-08-27 2005-09-25 Teva Pharma Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
JP2000256395A (ja) * 1999-01-07 2000-09-19 Takeda Chem Ind Ltd ポリオール類、その製造法および用途
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US6531130B1 (en) * 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US6930168B2 (en) * 2001-01-24 2005-08-16 The President And Fellows Of Harvard College Synthetic peptides for demyelinating conditions
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2004043995A2 (en) * 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device
US7495072B2 (en) * 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US8420605B2 (en) * 2005-09-07 2013-04-16 The University Of Strathclyde Hydrogel compositions

Also Published As

Publication number Publication date
IL233618A0 (en) 2014-08-31
IL233618A (en) 2016-05-31
EP1807467B1 (de) 2009-08-26
WO2006050122A1 (en) 2006-05-11
US8536305B2 (en) 2013-09-17
IL182581A0 (en) 2007-07-24
AU2005302500A1 (en) 2006-05-11
CA2583589C (en) 2012-04-24
JP5297653B2 (ja) 2013-09-25
ES2331015T3 (es) 2009-12-18
US20100234566A1 (en) 2010-09-16
DE602005016292D1 (de) 2009-10-08
CN101044188B (zh) 2010-08-04
US20100234272A1 (en) 2010-09-16
TWI307349B (en) 2009-03-11
JP2008518930A (ja) 2008-06-05
AR052321A1 (es) 2007-03-14
CA2583589A1 (en) 2006-05-11
US20080021200A1 (en) 2008-01-24
US8729229B2 (en) 2014-05-20
US20060154862A1 (en) 2006-07-13
CN101044188A (zh) 2007-09-26
US20100174048A1 (en) 2010-07-08
SI1807467T1 (sl) 2009-12-31
IL182581A (en) 2015-09-24
TW200634051A (en) 2006-10-01
AU2005302500B2 (en) 2008-11-27
EP1807467A1 (de) 2007-07-18

Similar Documents

Publication Publication Date Title
ATE440888T1 (de) Verfahren zur herstellung von glatiramer
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
DE602005019848D1 (de) Verfahren zur herstellung von tad- getrocknetem ti
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE399761T1 (de) Verfahren zur herstellung von dinitrilen
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
ATE479409T1 (de) Verfahren zur herstellung von saugkernen
ATE455105T1 (de) Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
ATE476411T1 (de) Verfahren zur herstellung von 3-pentennitril
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE480531T1 (de) Verfahren zur herstellung von benzopyran-2- olderivaten
ATE489015T1 (de) Verfahren zur herstellung von verschlüssen
ATE457969T1 (de) Verfahren zur herstellung von aloe-emodin
ATE308524T1 (de) Verfahren zur herstellung von aripiprazole
ATE399157T1 (de) Verfahren zur herstellung von telmisartan
DE602004022134D1 (de) Verfahren zur herstellung von dinitrilen
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE502005001997D1 (de) Verfahren zur herstellung von silanisierten kohlenstoff-nanoröhren
ATE453619T1 (de) Verfahren zur herstellung von hydroperoxiden
DE502004004318D1 (de) Verfahren zur herstellung von metall-matrix-verbundwerkstoffen
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE466843T1 (de) Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
ATE549314T1 (de) Verfahren zur herstellung von 4-aminochinazolinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1807467

Country of ref document: EP